How are things going with Verquvo?


anonymous

Guest
Interviewing for a position, any reps out there have thoughts on how long Merck will keep chronic care and Verquvo? Sounds like it's a skeleton crew...maybe naive, but that might mean less layoffs. Thoughts?
 


A career in Pharma sales is all about th ability to work in a very uncertain environment. Big sales or small, launch or mature product, it doesn't matter as it used to. If you are not in the industry and want to break in, take the Chronic Care postion if you can get it. If you are already in the business, scrutinize the opportunity more on what it pays you and, perhaps more importantly, what it does in terms of broadening your experience and adding to your professional network. Those things are more supportive of the security you seem interested in over the actual opportunity itself.
 


Most companies are moving to rare disease or oncology. Will your customer relationships in chronic care be able to help you launch new oncology products? This helps with long term future career stability.
 




Actually, Verquvo is a great drug. Pivitol trial is in a more advanced patient population than Entresto & SGLT2's were studied in. Awaiting data on a less advanced patient population that could change things, until then.....
 





Write your reply...